药品名称：注射用磷罗拉匹坦帕洛诺司琼 剂型：注射剂 格隆汇1月30日丨恒瑞医药(01276.HK)近日，江苏恒瑞医药股份有限公司子公司福建盛迪医药有限公司 收到国家药品监督管理局下发的《受理通知书》，公司注射用磷罗拉匹坦帕洛诺司琼(HR20013)的药品 上市许可申请获国家药监局受理。 受理号：CXHS2600019 申报阶段：上市 拟定适应症(或功能主治)：本品用于成年患者预防中度致吐性抗肿瘤药物引起的急性和迟发性恶心和呕 吐。 申请人：福建盛迪医药有限公司 ...

Group 1 - The core point of the article is that Hengrui Medicine's subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., has received approval for the environmental impact assessment of its Phase II construction project, with a total investment of 250 million yuan [1] - The "A-share Green Report" project aims to enhance the transparency of environmental information for listed companies, utilizing authoritative environmental regulatory data from 31 provinces and 337 cities [1] - The project includes monitoring the environmental performance of listed companies and their subsidiaries, providing professional data analysis and insights, and regularly updating the environmental risk rankings of these companies [1] Group 2 - The latest A-share Green Weekly Report (Issue No. 228) indicates that four listed companies have recently exposed environmental risks [1]

Core Insights - The biopharmaceutical industry is a key strategic emerging industry in Xiamen, Fujian Province, with over 1,800 companies expected by the end of 2025 and an industry scale nearing 100 billion yuan [1] - Xiamen has approved 8 new Class 1 drugs and over 60 new drug varieties for registration or clinical trials, along with 72 Class 3 medical devices, accounting for 90% of the total in Fujian Province [1] Regulatory Support - Xiamen's market regulatory authority emphasizes integrating regulation with service to support high-level innovation in the biopharmaceutical sector [1] - The Xiamen Market Supervision Administration has been enhancing regulatory capabilities, cultivating professional talent, and optimizing industry services to foster a high-quality development ecosystem [1] Technical Support and Quality Assurance - The Xiamen Food and Drug Quality Inspection Institute has successfully entered the national drug sampling quality analysis现场评议环节, having completed over 5,500 batches of sampling tasks since 2009 [2] - The institute is enhancing its inspection and testing capabilities through partnerships in research and development, focusing on cutting-edge technologies like cell and gene testing [2][3] - A new medical device testing center is under construction to meet the growing demand for testing in the biopharmaceutical industry, aiming to cover over 90% of the city's testing needs [3] Talent Development - The Xiamen Market Supervision Administration has implemented a comprehensive training system to enhance the professional skills of drug inspectors, with 183 inspectors certified by the end of last year [5][6] - The administration has established a "1+N" training system, organizing multiple training sessions to improve the regulatory workforce's capabilities [5][6] Industry Collaboration and Efficiency - The Xiamen Market Supervision Administration has facilitated faster product approvals, exemplified by the early approval of a drug by Fengdi Pharmaceutical, which benefited from professional guidance [7] - A dedicated working group has been established to support the high-quality development of the biopharmaceutical industry, streamlining administrative processes for over 60 licensing items [7][8] - Collaborative measures have been introduced to support the biopharmaceutical industry, including 20 initiatives focused on R&D innovation, clinical trials, and regulatory approvals [8]

受理号：CXHL2500996、CXHL2500997、CXHL2500998 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025年9月11日受理的HRS9531 注射液临床试验申请符合药品注册的有关要求，同意本品开展代谢相关脂肪性肝炎的临床试验。 剂型：注射剂 申请事项：临床试验 格隆汇12月12日丨恒瑞医药(01276.HK)公告，近日，江苏恒瑞医药股份有限公司子公司福建盛迪医药有 限公司收到国家药品监督管理局核准签发关于HRS9531注射液的《药物临床试验批准通知书》，将于近 期开展临床试验。 药物名称：HRS9531注射液 ...

Core Viewpoint - Heng Rui Medicine announced that its subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., has had its HRS-5635 injection included in the list of proposed breakthrough therapeutic products by the National Medical Products Administration, with a public announcement period of 7 days [1] Group 1 - HRS-5635 injection is a new generation liver-targeted HBV siRNA drug independently developed by the company [1] - The phase II clinical study results indicate that HRS-5635 has the potential to improve functional cure rates for chronic hepatitis B, while also demonstrating good safety characteristics [1]

Core Viewpoint - Heng Rui Medicine (600276.SH) announced that its subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., has received a "Notice of Acceptance" from the National Medical Products Administration (NMPA) for the drug listing application of HRS9531 injection [1] Group 1 - The drug HRS9531 is intended for long-term weight management in adults with a body mass index (BMI) of ≥28 kg/m² (obesity) or ≥24 kg/m² (overweight) with at least one weight-related comorbidity, such as high blood sugar, hypertension, dyslipidemia, obstructive sleep apnea, or fatty liver [1]